Répertoire du corps professoral

Gut microbiota biomarkers to personalize treatment of bladder cancer
Programme: Proof-of-Principle 2024: Microbial biomarkers of disease and therapeutic response
Organisme(s) subventionnaire(s): Weston Family Foundation
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 décembre 2024 au 30 avril 2027

Investigation multi-omiques des effets des acides gras oméga-3 et de la sélénonèine sur des organoïdes dérivés de patients atteints de cancer de la prostate.
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 2 juillet 2024 au 30 juillet 2026

Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma
Programme: UpCycle 2.1
Organisme(s) subventionnaire(s): Société de recherche sur le cancer
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 août 2022 au 31 juillet 2026

Developement of a prostate cancer vaccine
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 20 juillet 2022 au 1 mai 2025

What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer
Programme: Initiative SCC/IC-IRSC en prévention primaire du cancer
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada, Fondation du cancer du sein du Québec, Société canadienne du cancer
Type de financement: Subvention
Établissement tête: Université Laval
Du 15 janvier 2022 au 31 mars 2025

Targeting sex steroids to improve the response to bladder cancer immunotherapy
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2021 au 30 septembre 2026

Financements des 2 dernières années

Maintien de colonies de souris transgéniques exprimant des molécules de CMH humaines
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 22 mars 2022 au 21 mars 2023

Impact of lifestyle on gut barrier function, bacterial translocation and risk of prostate cancer
Organisme(s) subventionnaire(s): Weston Family Foundation
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 septembre 2020 au 30 avril 2023

En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers
Programme: Transformational Research
Organisme(s) subventionnaire(s): Weston Family Foundation
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juin 2020 au 30 avril 2024

Encadrements terminés dans les 5 dernières années

Fahimeh Aeineh Negin, Maîtrise en microbiologie-immunologie - avec mémoire

Benjamin Vittrant, Doctorat en médecine moléculaire

Sébastien Le Batteux, Doctorat en microbiologie-immunologie

Oscar Eduardo Molina, Doctorat en biologie cellulaire et moléculaire

Publications des 5 dernières années

Supplementary Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials 2023/03/31. Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas. DOI 10.1158/1078-0432.22487295

Supplementary Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials 2023/03/31. Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas. DOI 10.1158/1078-0432.22487295.v1

Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials 2023/03/31. Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas. DOI 10.1158/1078-0432.c.6532491

Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials 2023/03/31. Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas. DOI 10.1158/1078-0432.c.6532491.v1

Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA) Nutrients, 2023/03/11. Hanane Moussa, Karine Robitaille, Jean-François Pelletier, Roxane Tourigny, Yves Fradet, Louis Lacombe, Paul Toren, Michele Lodde, Rabi Tiguert, Thierry Dujardin, Yves Caumartin, Thierry Duchesne, Pierre Julien, Josée Savard, Caroline Diorio, Vincent Fradet. DOI 10.3390/nu15061369

Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspective. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022/05. Turcotte B, Bélanger L, Blais AS, Blouin AC, Bolduc S, Bolduc-Mokhtar A, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Pouliot F. DOI 10.5489/cuaj.7819

Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion. Molecular metabolism, 2022/05. Frégeau-Proulx L, Lacouture A, Berthiaume L, Weidmann C, Harvey M, Gonthier K, Pelletier JF, Neveu B, Jobin C, Bastien D, Bergeron A, Fradet Y, Audet-Walsh É. DOI 10.1016/j.molmet.2022.101516

Sex steroid modulation of macrophages within the prostate tumor microenvironment. American journal of clinical and experimental urology, 2022/04. Berrehail Z, Boibessot C, Gris T, Joncas FH, Gaignier F, Guillemette C, Lacombe L, Fradet Y, Toren P.

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022/03. Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Grivas P. DOI 10.1158/1078-0432.ccr-21-3089

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. The Lancet. Oncology, 2022/02. Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, GALAHAD investigators. DOI 10.1016/s1470-2045(21)00757-9

Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clinical and translational medicine, 2022/01. Boibessot C, Molina O, Lachance G, Tav C, Champagne A, Neveu B, Pelletier JF, Pouliot F, Fradet V, Bilodeau S, Fradet Y, Bergeron A, Toren P. DOI 10.1002/ctm2.581

Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer. Asian journal of andrology, 2022/01. Kourbanhoussen K, Joncas FH, D Wallis CJ, Hovington H, Dagenais F, Fradet Y, Guillemette C, Lacombe L, Toren P. DOI 10.4103/aja.aja_58_21

A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota. Cancer discovery, 2022/01. Messaoudene M, Pidgeon R, Richard C, Ponce M, Diop K, Benlaifaoui M, Nolin-Lapalme A, Cauchois F, Malo J, Belkaid W, Isnard S, Fradet Y, Dridi L, Routy B. DOI 10.1158/2159-8290.cd-21-0808

Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate. Cancers, 2021/12. Diop MK, Albadine R, Kougioumoutzakis A, Delvoye N, Hovington H, Bergeron A, Fradet Y, Saad F, Trudel D. DOI 10.3390/cancers13246243

Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy. Clinical nutrition ESPEN, 2021/12. Fradet S, Pelletier JF, Singbo N, Lacombe L, Toren P, Lodde M, Dujardin T, Tiguert R, Fradet Y, Robitaille K, Fradet V. DOI 10.1016/j.clnesp.2021.12.011

Résumés AUQ 2021. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021/11. DOI 10.5489/cuaj.7674

Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. Journal of biomedical optics, 2021/11. Plante A, Dallaire F, Grosset AA, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Leblond F. DOI 10.1117/1.jbo.26.11.116501

¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021/10. Otis-Chapados S, Goulet CR, Dubois G, Lavallée É, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F. DOI 10.5489/cuaj.7107

Northeastern Section of the American Urological Association 73rd Annual Meeting Abstracts. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021/09. DOI 10.5489/cuaj.7599

Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA. International journal of molecular sciences, 2021/09. Lambert M, Benmoussa A, Diallo I, Ouellet-Boutin K, Dorval V, Majeau N, Joly-Beauparlant C, Droit A, Bergeron A, Têtu B, Fradet Y, Pouliot F, Provost P. DOI 10.3390/ijms22189757

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. The Lancet. Oncology, 2021/05. Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, KEYNOTE-361 Investigators. DOI 10.1016/s1470-2045(21)00152-2

Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. Molecular cancer research : MCR, 2020/12. Gevariya N, Lachance G, Robitaille K, Joly Beauparlant C, Beaudoin L, Fournier É, Fradet Y, Droit A, Julien P, Marette A, Bergeron A, Fradet V. DOI 10.1158/1541-7786.mcr-20-0316

Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression. Oncoimmunology, 2020/12. Vittrant B, Bergeron A, Molina OE, Leclercq M, Légaré XP, Hovington H, Picard V, Martin-Magniette ML, Livingstone J, Boutros PC, Collins C, Fradet Y, Droit A. DOI 10.1080/2162402x.2020.1851950

Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth. Prostaglandins, leukotrienes, and essential fatty acids, 2020/11. Bilodeau JF, Gevariya N, Larose J, Robitaille K, Roy J, Oger C, Galano JM, Bergeron A, Durand T, Fradet Y, Julien P, Fradet V. DOI 10.1016/j.plefa.2020.102215

Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer. Frontiers in genetics, 2020/11. Vittrant B, Leclercq M, Martin-Magniette ML, Collins C, Bergeron A, Fradet Y, Droit A. DOI 10.3389/fgene.2020.550894

Building a Canadian Translational Bladder Cancer Research Network. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020/10. Koti M, Berman DM, Siemens DR, Lange D, Wang E, Toren P, Eigl BJ, Hardy C, Purves R, Fradet V, Fradet Y, Mansure J, Kassouf W, Black PC, Canadian Bladder Cancer Research Network. DOI 10.5489/cuaj.6887

A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020/10. Turcotte B, Paquet S, Blais AS, Blouin AC, Bolduc S, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Fradet Y, Lacombe L, Pouliot F. DOI 10.5489/cuaj.6862

Northeastern Section of the AUA 72nd Annual Meeting Abstracts Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020/09.

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Oncology, 2020/09. Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, DANUBE study investigators. DOI 10.1016/s1470-2045(20)30541-6

Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. PLoS medicine, 2020/08. Grosset AA, Dallaire F, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Trudel D. DOI 10.1371/journal.pmed.1003281

Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. World journal of urology, 2020/07. Toren P, Brisson H, Simonyan D, Hovington H, Lacombe L, Bergeron A, Fradet Y. DOI 10.1007/s00345-020-03358-x

Message from our President Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020/06. Zorn K, Bhojani N, Elterman D, Goldenberg S, So A, Paterson R, Desai M, Roehrborn R, Kaplan S, Gilling P, Berto F, Wang Z, Bjazevic J, Filler G, Romao R.

Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. British journal of cancer, 2020/02. Lévesque E, Labriet A, Hovington H, Allain ÉP, Melo-Garcia L, Rouleau M, Brisson H, Turcotte V, Caron P, Villeneuve L, Leclercq M, Droit A, Guillemette C. DOI 10.1038/s41416-020-0749-2

Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. The Journal of urology, 2020/01. Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Pinthus J. DOI 10.1097/ju.0000000000000714

Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nature medicine, 2019/10. Houlahan KE, Shiah YJ, Gusev A, Yuan J, Ahmed M, Shetty A, Ramanand SG, Yao CQ, Bell C, O'Connor E, Huang V, Fraser M, Heisler LE, Livingstone J, Boutros PC. DOI 10.1038/s41591-019-0579-z

Résumés AUQ 2019. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019/09. DOI 10.5489/cuaj.6229

Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. The Prostate, 2019/09. Joncas FH, Lucien F, Rouleau M, Morin F, Leong HS, Pouliot F, Fradet Y, Gilbert C, Toren P. DOI 10.1002/pros.23901

Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive? Clinical genitourinary cancer, 2019/08. McMartin C, Lacombe L, Fradet V, Fradet Y, Lodde M, Toren P. DOI 10.1016/j.clgc.2019.07.016

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 2019/06. Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Bajorin DF. DOI 10.1093/annonc/mdz127

Large-Scale Automatic Feature Selection for Biomarker Discovery in High-Dimensional OMICs Data. Frontiers in genetics, 2019/05. Leclercq M, Vittrant B, Martin-Magniette ML, Scott Boyer MP, Perin O, Bergeron A, Fradet Y, Droit A. DOI 10.3389/fgene.2019.00452

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. The New England journal of medicine, 2019/05. Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, TITAN Investigators. DOI 10.1056/nejmoa1903307

Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. Radiation oncology (London, England), 2019/04. Trinh VQ, Benzerdjeb N, Chagnon-Monarque S, Dionne N, Delouya G, Kougioumoutzakis A, Sirois J, Albadine R, Latour M, Mes-Masson AM, Hovington H, Trudel D. DOI 10.1186/s13014-019-1267-3

Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. Urologic oncology, 2019/03. Haider M, Ladurner C, Mayr R, Tandogdu Z, Fritsche HM, Fradet V, Comploj E, Pycha A, Lemire F, Lacombe L, Fradet Y, Toren P, Lodde M. DOI 10.1016/j.urolonc.2019.01.017

Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell, 2019/02. Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, He HH. DOI 10.1016/j.cell.2019.01.025

Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine connections, 2019/02. Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F. DOI 10.1530/ec-18-0476

A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019/02. Lévesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C. DOI 10.1158/1055-9965.epi-18-1002

Canadian Urological Association guideline: Muscle-invasive bladder cancer. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019/01. DOI 10.5489/cuaj.5902